OXYCODONE TEREPHTHALATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C18H21NO4.C8H6O4
Molecular Weight	796.8581
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=C(C=C1)C(O)=O.COC2=C3O[C@H]4C(=O)CC[C@@]5(O)[C@H]6CC(C=C2)=C3[C@@]45CCN6C.COC7=C8O[C@H]9C(=O)CC[C@@]%10(O)[C@H]%11CC(C=C7)=C8[C@@]9%10CCN%11C

InChI

InChIKey=BTEYIHUKHHAVAN-KDKWOIFOSA-N

InChI=1S/2C18H21NO4.C8H6O4/c2*1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;9-7(10)5-1-2-6(4-3-5)8(11)12/h2*3-4,13,16,21H,5-9H2,1-2H3;1-4H,(H,9,10)(H,11,12)/t2*13-,16+,17+,18-;/m11./s1

HIDE SMILES / InChI

Molecular Formula	C18H21NO4
Molecular Weight	315.3636
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C8H6O4
Molecular Weight	166.1308
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html

Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mu opioid receptor 231 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2752	500.0 nM [EC50]
Kappa opioid receptor 115 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2752	16000.0 nM [EC50]
Delta opioid receptor 81 Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2752	4000.0 nM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Acute and chronic pain 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf	Primary	Approved 8583	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date 1950
Opioid-related disorders 6 Sources: https://clinicaltrials.gov/ct2/show/NCT00158184	Primary	Phase II 1147	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date 1950
Osteoarthritis 157 Sources: https://clinicaltrials.gov/ct2/show/NCT00985621	Primary	Phase III 665	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date 1950

C_max

Value	Dose	Analyte	Population
22.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
39.3 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
19 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
17.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
15.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
12.9 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
128.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
268.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
105 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
133 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
113.3 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
99 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
3.55 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
3.85 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
2.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
3.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED

F_unbound

Value	Dose	Analyte	Population
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg 1 times / day single, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/	healthy, 30 years Health Status: healthy Age Group: 30 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/	Other AEs: Pulmonary edema... Other AEs: Pulmonary edema Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 1.7%) Dizziness (grade 1-2, 1.7%) Abdominal pain (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Disc. AE: Headache, Vomiting... AEs leading to discontinuation/dose reduction: Headache (grade 1-2, 0.8%) Vomiting (grade 1-2, 0.8%) Nausea (grade 1-2, 0.8%) Somnolence (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 6.3%) Dizziness (grade 1-2, 4.8%) Confusion (grade 1-2, 3.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Disc. AE: Vomiting, Flu syndrome... AEs leading to discontinuation/dose reduction: Vomiting (grade 1-2, 0.8%) Flu syndrome (grade 1-2, 0.8%) Confusion (grade 1-2, 0.8%) Fatigue (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf
6 mg 2 times / day single, oral Studied dose Dose: 6 mg, 2 times / day Route: oral Route: single Dose: 6 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/	healthy, mean age 33 years Health Status: healthy Age Group: mean age 33 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (11.4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/
15 mg 1 times / day single, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: single Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf	healthy, mean age 36 years Health Status: healthy Age Group: mean age 36 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946		substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Nav1.5 116	CYP3A5 446 P-gp 2052 UGT2B7 456 UGT2B4 278	P-gp 301 BCRP 101

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
BCRP 985	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802418/	yes
P-gp 1932	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401600/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27692933/	major
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27692933/	minor
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/	yes
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401600/	yes
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21011lbl.pdf#page=7; https://pubmed.ncbi.nlm.nih.gov/21142269/ Page: 7.0	yes	yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21011lbl.pdf#page=7; https://pubmed.ncbi.nlm.nih.gov/21142269/ Page: 7.0
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/; https://pubmed.ncbi.nlm.nih.gov/21142269/	yes	yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/; https://pubmed.ncbi.nlm.nih.gov/21142269/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.5 119	inhibitor 2237 Sources: https://europepmc.org/article/med/29722437
hERG 2263	inhibitor 2237 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670374/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7852	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7852
ZINC	ZINC000000403533	http://zinc15.docking.org/substances/ZINC000000403533

PubMed

Title	Date	PubMed
Opioid formulations: tailoring to the needs in chronic pain.	2001	11798229
Strategies for the treatment of cancer pain in the new millennium.	2001	11434451
The preemptive analgesic effect of intraarticular bupivacaine and morphine after ambulatory arthroscopic knee surgery.	2001 Apr	11273927
Time-release analgesic drug causes fatal overdoses in United States.	2001 Aug	11483541
"No, Duke. No divorce".	2001 Aug 20	11550441
The potent perils of a miracle drug.	2001 Jan 8	11194416
Federal reports say oxycodone abuse is on the rise.	2001 Jul 1	11449872
'Not an appropriate use'. Did the makers of OxyContin push too hard?	2001 Jul 2	11447650
Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine.	2001 Jul-Aug	11441321
Controlled-release oxycodone hydrochloride (OxyContin).	2001 Sep	11855610
Managing postoperative pain.	2001 Sep	11584617
Hydromorphone for acute and chronic pain.	2002	11869661
Oxy's offspring.	2002 Apr 22	11974393
Minimal interaction between gatifloxacin and oxycodone.	2002 Aug	12162476
Treatment of postherpetic neuralgia: a systematic review of the literature.	2002 Feb	11978209
Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children.	2002 Feb	11882229
Treatment of painful sickle cell leg ulcers with topical opioids.	2002 Feb 1	11822360
Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain.	2002 Jan	11833838
A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care.	2002 Jan-Feb	11803309
Safety and efficacy of controlled-release oxycodone: a systematic literature review.	2002 Jul	12126222
Gateways to clinical trials.	2002 Jul-Aug	12224444
An evaluation of the efficacy and tolerability of oral tramadol hydrochloride tablets for the treatment of postsurgical pain in children.	2002 Jun	12032009
Preoperative administration of controlled-release oxycodone for the management of pain after ambulatory laparoscopic tubal ligation surgery.	2002 May	12031758
Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes.	2002 Nov	12388636
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.	2002 Oct	12423011
Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases.	2002 Oct	12422999
Oxycontin--misuse and abuse.	2002 Summer	12108125

Patents

Sample Use Guides

In Vivo Use Guide

For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.

Route of Administration: Oral

In Vitro Use Guide

Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:54:14 GMT 2025` Edited by `admin` on `Mon Mar 31 17:54:14 GMT 2025`
Record UNII	M04XWV43UF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CODOXY COMPONENT OXYCODONE TEREPHTHALATE

Preferred Name

English

OXYCODONE TEREPHTHALATE

Common Name

English

PERCODAN-DEMI COMPONENT OXYCODONE TEREPHTHALATE

Common Name

English

14-HYDROXYDIHYDROCODEINONE TEREPHTHALATE (2:1)

Common Name

English

MORPHINAN-6-ONE, 4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYL-, 1,4-BENZENEDICARBOXYLATE (2:1 SALT), (5.ALPHA.)

Common Name

English

ROXIPRIN COMPONENT OXYCODONE TEREPHTHALATE

Common Name

English

OXYCODONE TEREPHTHALATE [USP IMPURITY]

Common Name

English

OXYCODONE TEREPHTHALATE [MART.]

Common Name

English

OXYCODONE TEREPHTHALATE [USP MONOGRAPH]

Common Name

English

4,5?-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one 1,4-benzenedicarboxylate (2:1 salt)

Common Name

English

OXYCODONE TEREPHTHALATE [ORANGE BOOK]

Common Name

English

OXYCODONE TEREPHTHALATE [VANDF]

Common Name

English

Oxycodone terephthalate [WHO-DD]

Common Name

English

Classification Tree Code System Code

DEA NO.

9143